Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab    GEN   DK0010272202

GENMAB

(GEN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Genmab : A good level to buy

share with twitter share with LinkedIn share with facebook
share via e-mail
02/07/2019 | 05:42am EDT
long trade
Target price hit
Entry price : 962DKK | Target : 1020DKK | Stop-loss : 928.7DKK | Potential : 6.03%
Shares in Genmab show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed.
Investors have an opportunity to buy the stock and target the DKK 1020.
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | MarketScreener
Full-screen chart
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has poor fundamentals for a short-term investment strategy.

Strengths
  • The close medium term support offers good timing for purchasing the stock.
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Historically, the company has been releasing figures that are above expectations.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46.74 times its estimated earnings per share for the ongoing year.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Genmab : A good level to buy

Anaïs Lozach
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (DKK)
Sales 2019 4 697 M
EBIT 2019 2 209 M
Net income 2019 1 824 M
Finance 2019 7 722 M
Yield 2019 -
P/E ratio 2019 37,80
P/E ratio 2020 33,57
EV / Sales 2019 13,1x
EV / Sales 2020 10,9x
Capitalization 69 195 M
Upcoming event on GENMAB
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 1 328  DKK
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Mats Gunnar Pettersson Chairman
Michael K. Bauer SVP, Head-Operations, Research & Development
David Andrew Eatwell Chief Financial Officer & Executive Vice President
Anders Gersel Pedersen Deputy Chairman
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB5.11%10 418
GILEAD SCIENCES0.64%80 255
VERTEX PHARMACEUTICALS1.48%42 991
REGENERON PHARMACEUTICALS-10.75%35 789
SAREPTA THERAPEUTICS INC6.88%8 594
BLUEBIRD BIO INC38.17%7 532